Iloprost

證據等級: L5

預測適應症: 9 個

Iloprost: From Pulmonary Arterial Hypertension to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Iloprost is a synthetic prostacyclin (PGI2) analogue, a drug class clinically established for treating pulmonary arterial hypertension (PAH) through pulmonary vasodilation and platelet inhibition. The TxGNN model's top-ranked prediction is Hypotrichosis Simplex of the Scalp, but this candidate currently has no supporting clinical trials or literature — it is a pure model-derived hypothesis at this stage.

Quick Overview

Item	Content
Original Indication	Pulmonary Arterial Hypertension (PAH) — based on known drug class; structured original-indication data was not available in this evidence pack
Predicted New Indication	Hypotrichosis Simplex of the Scalp
TxGNN Prediction Score	99.45%
Evidence Level	L5
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, iloprost is a synthetic prostacyclin (PGI2) analogue that activates the IP receptor/cAMP pathway, producing pulmonary vasodilation and platelet aggregation inhibition — the core pharmacological mechanism underlying its established use in PAH.

The mechanistic rationale supplied for this candidate is speculative and drawn from a different drug class by analogy: prostaglandin analogues such as bimatoprost and latanoprost are known to promote eyelash/hair growth, and it is theorized that prostacyclin receptor pathways might have some overlapping activity with prostaglandin receptor pathways. However, this is a class-level inference, not iloprost-specific evidence, and no trial or publication data currently supports it.

Because hypotrichosis simplex of the scalp is a genetically driven hair-follicle disorder with no established link to vasodilatory/antiplatelet pharmacology, this prediction should be treated as an early-stage hypothesis requiring dedicated mechanistic and preclinical validation before further evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Iloprost is not marketed in Finland; no marketing authorization records are available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Hypotrichosis Simplex of the Scalp) has a high TxGNN score but zero supporting clinical trials or literature, and its mechanistic rationale is only a cross-class analogy rather than iloprost-specific evidence — insufficient to advance past S0.

To proceed, the following is needed:

Preclinical/mechanistic studies directly linking iloprost's PGI2/IP-receptor pathway to hair follicle biology
Confirmed original indication and MOA data (currently a data gap despite a successful DrugBank query)
TFDA/Fimea package insert warnings and contraindications (currently blocking per data gap DG001)

Note: Among the other TxGNN-predicted indications in this evidence pack, Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (rank 3) has materially stronger evidence — 1 completed trial and 20 literature references, Evidence Level L2, recommendation "Proceed with Guardrails" — and PAH-associated with connective tissue disease (rank 5) and HIV infection (rank 6) also show moderate evidence (L2–L3). These PAH-subtype candidates are mechanistically consistent with iloprost's known pharmacology and warrant prioritized evaluation ahead of the hypotrichosis candidate.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.